Symposium on

Modern Trends in Radiopharmaceutical Sciences

Institute of Neurosciences and Medicine, INM-5: Nuclear Chemistry
Forschungszentrum Jülich (FZJ), Germany, 05 May 2009
Hörsaal, Gebäude 05.3


08:45 Uhr

Welcome and opening

Prof. Dr. S. Schmidt, Board of Directors, FZJ, Jülich

H.H. Coenen, President SRS, FZJ, Jülich

09:00 Uhr

Can photons meet the challenge of producing Mo-99?

T. Ruth, TRIUMF, Vancouver

09:30 Uhr

Nuclear data for the production of non-standard PET-radionuclides.

S.M. Qaim, FZJ, Jülich

10:00 Uhr

Preparation and use of high specific activity radiometals.

C. Cutler, University of Missouri, Columbia, MO

10:30 Uhr

Coffee break

11:00 Uhr

Recent attempts for the application of Re-188 in cancer radiotherapy.

U. Mazzi, University of Padua, Padua

11:30 Uhr

New studies with radiolabled bombesin derivatives for imaging and therapy.

W. Volkert, University of Missouri, Columbia, MO

12:00 Uhr

Hypoxic tumour stem cell as a target for PET imaging/radiotherapy.

Y. Fujibayashi, University of Fukui, Fukui

12:30 Uhr

Lunch break

14:00 Uhr

B12-derivates – A promising tumour biomarker.

P. A. Schubiger, ETH/PSI, Zürich

14:30 Uhr

Multimeric receptor binding and the role of ligand rigidity.

M. Eisenhut, Deutsches Krebsforschungszentrum (DKFZ),

15:00 Uhr

Radiopharmaceuticals for imaging PgP function with PET;

[11C]Verapamil, its radiometabolite [11C]D617

and the new radiopharmaceutical [11C]Laniquidar.

A.D. Windhorst, Free University of Amsterdam, Amsterdam

15:30 Uhr

Coffee break

16:00 Uhr

Changes in latitudes, changes in attitudes.

W.C. Eckelman, Molecular Tracer LLC, Bethesda, MD

16:30 Uhr

EU and US regulatory considerations for PET radiopharmaceuticals.

S. Schwarz, Washington University, St. Louis, MO

17:00 Uhr

Training program for PET radiopharmaceutical sciences:

Addressing a global shortage.

S. Mcquarrie, University of Alberta, Edmonton

17:30 Uhr

Round table discussion

18:00 Uhr

Closing, farewell